-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, WuXi Junuo announced that the China National Medical Products Administration (NMPA) has accepted its CD19-targeting autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product, Benoda® (Sweden).
The new indication marketing application is based on a single-arm, multi-center, pivotal clinical study (RELIANCE study) B cohort of Benoda® for the treatment of Chinese adult patients with r/r B-cell non-Hodgkin lymphoma.
Professor Song Yuqin, Chief Physician of the Lymphoma Department of Peking University Cancer Hospital and Director of the Chinese Society of Clinical Oncology, said at the ASH annual meeting: "The data from the RELIANCE study shows that Benoda has demonstrated excellent clinical efficacy and safety in patients with r/r FL.